Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David L Boyle

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
ACR Open Rheumatology|December 25, 2019
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis Fibroblast-like SynoviocytesDeepa Hammaker, Gyrid Nygaard, Amanda Kuhs, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2002
Regional analysis of p53 mutations in rheumatoid arthritis synoviumYuji Yamanishi, David L Boyle, Sanna Rosengren, et al.
Brain Sciences|July 27, 2022
Lipopolysaccharide Exposure Differentially Alters Plasma and Brain Inflammatory Markers in Adult Male and Female RatsHannah A Nonoguchi, Timothy Wee Shang Kouo, Sandhya Kortagere, et al.
Genome Medicine|May 2, 2013
An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotypeJohn W Whitaker, Robert Shoemaker, David L Boyle, et al.
Plos One|April 23, 2015
Integrative omics analysis of rheumatoid arthritis identifies non-obvious therapeutic targetsJohn W Whitaker, David L Boyle, Beatrix Bartok, et al.
Arthritis Research & Therapy|January 12, 2005
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritisYuji Yamanishi, David L Boyle, Douglas R Green, et al.
Plos One|August 20, 2015
Correction: Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic TargetsJohn W Whitaker, David L Boyle, Beatrix Bartok, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2006
Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritisTomoyuki Inoue, David L Boyle, Maripat Corr, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 3, 2006
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytesHoon-Suk Cha, David L Boyle, Tomoyuki Inoue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 30, 2009
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expressionToshio Yoshizawa, Deepa Hammaker, David L Boyle, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
ACR Open Rheumatology|December 25, 2019
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis Fibroblast-like SynoviocytesDeepa Hammaker, Gyrid Nygaard, Amanda Kuhs, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2002
Regional analysis of p53 mutations in rheumatoid arthritis synoviumYuji Yamanishi, David L Boyle, Sanna Rosengren, et al.
Brain Sciences|July 27, 2022
Lipopolysaccharide Exposure Differentially Alters Plasma and Brain Inflammatory Markers in Adult Male and Female RatsHannah A Nonoguchi, Timothy Wee Shang Kouo, Sandhya Kortagere, et al.
Genome Medicine|May 2, 2013
An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotypeJohn W Whitaker, Robert Shoemaker, David L Boyle, et al.
Plos One|April 23, 2015
Integrative omics analysis of rheumatoid arthritis identifies non-obvious therapeutic targetsJohn W Whitaker, David L Boyle, Beatrix Bartok, et al.
Arthritis Research & Therapy|January 12, 2005
p53 tumor suppressor gene mutations in fibroblast-like synoviocytes from erosion synovium and non-erosion synovium in rheumatoid arthritisYuji Yamanishi, David L Boyle, Douglas R Green, et al.
Plos One|August 20, 2015
Correction: Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic TargetsJohn W Whitaker, David L Boyle, Beatrix Bartok, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 2006
Mitogen-activated protein kinase kinase 3 is a pivotal pathway regulating p38 activation in inflammatory arthritisTomoyuki Inoue, David L Boyle, Maripat Corr, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 3, 2006
A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytesHoon-Suk Cha, David L Boyle, Tomoyuki Inoue, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 30, 2009
Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expressionToshio Yoshizawa, Deepa Hammaker, David L Boyle, et al.
Pageof 12